Gujarat kidney and super speciality ltd posts strong Q3FY26 performance

Gujarat Kidney And Super Speciality Limited reported a solid financial performance for Q3FY26, driven by operational efficiency and improved scale across its healthcare services portfolio. The company recorded healthy growth in both standalone and consolidated revenue, while profitability improved sequentially and year-on-year, reflecting effective cost control and stable demand across its hospital operations.

Q3FY26 Financial Highlights

Standalone Performance

Revenue from operations stood at ₹976.45 lakh, up 14.8% YoY

Net profit increased to ₹233.26 lakh, marking 5.5% YoY growth

Earnings per share (EPS) came in at ₹0.41

Nine-month FY26 revenue rose 13.7% YoY to ₹3,085.70 lakh

Consolidated Performance

Revenue from operations surged to ₹2,324.59 lakh, up 97.2% YoY

Net profit grew 46.2% YoY to ₹370.62 lakh

EPS improved to ₹0.52

Growth was supported by contributions from subsidiary hospitals and expanded operational scale

Cost Control and Operational Efficiency

The company maintained disciplined cost management during the quarter. Standalone expenses remained stable, while consolidated expenses increased in line with higher activity levels. Employee costs and finance expenses were kept under control, supporting margin expansion.

Governance and Compliance

The results were approved by the Board on 14 February 2026 and reviewed by statutory auditors Y M Shah & Co., who issued an unmodified limited review report. The company confirmed full compliance with SEBI LODR Regulations, 2015.